Opinion|Videos|February 21, 2025

CARTITUDE-4 Highlights: Cilta-Cel vs Standard of Care in R/R MM

Panelists discuss how CARTITUDE-4 demonstrated superior progression-free survival and overall response rates with ciltacabtagene autoleucel (cilta-cel) compared with standard treatment options in relapsed/refractory multiple myeloma (R/R MM) patients who received 1 to 3 prior lines of therapy.

Episodes in this series


Latest CME